The pan-Canadian Pharmaceutical Alliance (PCPA, stylized as pCPA), previously the Pan-Canadian Pricing Alliance and the Generic Value Price Initiative[1] is an alliance between the provinces and territories of Canada to combine their bargaining power to negotiate lower prices on pharmaceutical drugs.[2][3]
History
editSupport for inter-provincial coordination on price negotiations for pharmaceuticals began in August 2010 after a meeting of provincial premiers.[4] The pCPA initially comprised nine provinces and Yukon, with Quebec joining in 2014.[2] As of 2023, all provinces and territories are members of the Alliance.[4]
The pCPA conducted negotiations for prices on ten drugs in its first three years, including for eculizumab, and estimated it had saved approximately $50,000,000.[4]
References
edit- ^ A. Scott Carson; Kim Richard Nossal; Jeffrey A. Dixon (2015). Toward a Healthcare Strategy for Canadians. School of Policy Studies, Queen's University. p. 40. ISBN 978-1-55339-439-6.
- ^ a b Joel Lexchin (27 October 2016). Private Profits versus Public Policy: The Pharmaceutical Industry and the Canadian State. University of Toronto Press, Scholarly Publishing Division. p. 181. ISBN 978-1-4426-1961-6.
- ^ Cummings, Madeleine (September 3, 2020). "Why speed is key to securing COVID-19 vaccines". CBC News.
- ^ a b c Husereau, Don; Dempster, William; Blanchard, Adrienne; Chambers, Johanne (2014). "Evolution of Drug Reimbursement in Canada: The Pan-Canadian Pharmaceutical Alliance for New Drugs". Value in Health. 17 (8): 888–894. doi:10.1016/j.jval.2014.08.2673. ISSN 1098-3015.